Symbols / TTOO $0.00 +0.00%
TTOO Chart
About
T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 14.02K |
| Enterprise Value | 16.91M | Income | -42.95M | Sales | 7.68M |
| Book/sh | -0.62 | Cash/sh | 0.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 113 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | 0.00 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.41 | EV/Sales | 2.20 | Quick Ratio | 0.17 |
| Current Ratio | 0.40 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.03 | EPS next Y | -1.19 | EPS Growth | — |
| Revenue Growth | 34.90% | Earnings | 2025-06-11 16:00 | ROA | -84.85% |
| ROE | — | ROIC | — | Gross Margin | -247.83% |
| Oper. Margin | -5.12% | Profit Margin | 0.00% | Shs Outstand | 28.05M |
| Shs Float | 11.90M | Short Float | 4.87% | Short Ratio | 0.71 |
| Short Interest | — | 52W High | 0.18 | 52W Low | 0.00 |
| Beta | 0.88 | Avg Volume | 51.84K | Volume | 35.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-16.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-30 | main | Canaccord Genuity | Hold → Hold | $5 |
| 2024-04-29 | main | Canaccord Genuity | Hold → Hold | $3 |
- TTOO Stock Price and Chart — OTC:TTOO - TradingView Sun, 25 Jan 2026 08
- T2 Biosystems to be delisted from Nasdaq - Investing.com ue, 11 Feb 2025 08
- T2 Biosystems (TTOO) Stock Gains on Monkeypox Test News - InvestorPlace Wed, 10 Aug 2022 07
- T2 Biosystems Stock Price Forecast. Should You Buy TTOO? - StockInvest.us ue, 01 Dec 2020 18
- T2 Biosystems Inc (TTOO) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance Fri, 11 Oct 2024 07
- T2 Biosystems Stock Is a Buy Amid Breakthrough in COVID-19 Testing - Market Realist ue, 12 Jan 2021 08
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire Mon, 02 Oct 2023 07
- T2 Biosystems (NASDAQ: TTOO) up 46% - more than just meme stock nonsense - Dhaka Tribune Mon, 18 Sep 2023 07
- T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Stock Titan ue, 27 Aug 2024 07
- Why Shares of T2 Biosystems Are Falling Friday - The Motley Fool Fri, 13 Oct 2023 07
- T2 Biosystems Enhances Governance and Leadership Stability - Nasdaq Fri, 03 Jan 2025 08
- TTOO Price Forecast: Can (NASDAQ: TTOO) Thrust Above $1 Mark? - The Coin Republic ue, 22 Aug 2023 07
- Medical diagnostics firm T2 Biosystems cuts ‘substantially all’ workers - The Business Journals ue, 18 Feb 2025 08
- T2 Biosystems stock plunges to 52-week low of $0.55 - Investing.com ue, 12 Nov 2024 08
- T2 Biosystems (TTOO) Stock: Mixed Signals in Volatile Market - StockInvest.us ue, 11 Jul 2023 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 55 | 133.0 | — | Sale at price 2.42 per share. | ELSBREE DAVID B | Director | — | 2024-09-13 00:00:00 | D |
| 1 | 1824800 | nan | — | — | CR GROUP, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-09 00:00:00 | I |
| 2 | 4748335 | — | — | Stock Award(Grant) at price 0.00 per share. | CR GROUP, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-03 00:00:00 | I |
| 3 | 3280618 | — | — | Stock Award(Grant) at price 0.00 per share. | CR GROUP, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-12 00:00:00 | I |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -46.79M | -53.96M | -40.12M |
| TotalUnusualItems | 2.91M | -913.00K | 1.01M |
| TotalUnusualItemsExcludingGoodwill | 2.91M | -913.00K | 1.01M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -50.08M | -62.00M | -49.24M |
| ReconciledDepreciation | 859.00K | 1.05M | 2.54M |
| ReconciledCostOfRevenue | 15.36M | 21.01M | 20.70M |
| EBITDA | -43.88M | -54.87M | -39.11M |
| EBIT | -44.73M | -55.92M | -41.65M |
| NetInterestIncome | -5.34M | -6.08M | -7.48M |
| InterestExpense | 5.34M | 6.08M | 7.60M |
| InterestIncome | 8.00K | 112.00K | |
| NormalizedIncome | -52.99M | -61.09M | -50.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -50.08M | -62.00M | -49.24M |
| TotalExpenses | 54.35M | 77.35M | 71.03M |
| TotalOperatingIncomeAsReported | -49.66M | -55.20M | -42.97M |
| DilutedAverageShares | 2.61M | 51.00K | 1.59M |
| BasicAverageShares | 2.61M | 51.00K | 1.59M |
| DilutedEPS | -19.19 | -1.23K | -31.00 |
| BasicEPS | -19.19 | -1.23K | -31.00 |
| DilutedNIAvailtoComStockholders | -50.08M | -62.33M | -49.24M |
| NetIncomeCommonStockholders | -50.08M | -62.33M | -49.24M |
| PreferredStockDividends | 330.00K | ||
| NetIncome | -50.08M | -62.00M | -49.24M |
| NetIncomeIncludingNoncontrollingInterests | -50.08M | -62.00M | -49.24M |
| NetIncomeContinuousOperations | -50.08M | -62.00M | -49.24M |
| PretaxIncome | -50.08M | -62.00M | -49.24M |
| OtherIncomeExpense | 2.42M | -874.00K | 1.22M |
| OtherNonOperatingIncomeExpenses | -495.00K | 39.00K | 206.00K |
| SpecialIncomeCharges | -2.51M | -151.00K | |
| ImpairmentOfCapitalAssets | 2.51M | 151.00K | |
| GainOnSaleOfSecurity | 5.42M | -762.00K | 1.01M |
| NetNonOperatingInterestIncomeExpense | -5.34M | -6.08M | -7.48M |
| InterestExpenseNonOperating | 5.34M | 6.08M | 7.60M |
| InterestIncomeNonOperating | 8.00K | 112.00K | |
| OperatingIncome | -47.15M | -55.05M | -42.97M |
| OperatingExpense | 38.98M | 56.34M | 50.33M |
| ResearchAndDevelopment | 14.15M | 25.71M | 21.80M |
| SellingGeneralAndAdministration | 24.83M | 30.62M | 28.53M |
| GrossProfit | -8.17M | 1.29M | 7.36M |
| CostOfRevenue | 15.36M | 21.01M | 20.70M |
| TotalRevenue | 7.19M | 22.30M | 28.06M |
| OperatingRevenue | 7.19M | 22.30M | 28.06M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 4.06M | 77.17K | 1.66M |
| ShareIssued | 4.06M | 77.17K | 1.66M |
| NetDebt | 25.59M | 39.32M | 25.55M |
| TotalDebt | 49.50M | 59.22M | 58.32M |
| TangibleBookValue | -28.04M | -39.66M | -12.90M |
| InvestedCapital | 13.25M | 10.00M | 34.89M |
| WorkingCapital | -30.96M | 9.23M | 32.71M |
| NetTangibleAssets | -28.04M | -39.66M | -12.90M |
| CapitalLeaseObligations | 8.21M | 9.57M | 10.53M |
| CommonStockEquity | -28.04M | -39.66M | -12.90M |
| TotalCapitalization | -28.04M | 10.00M | 34.89M |
| TotalEquityGrossMinorityInterest | -28.04M | -39.66M | -12.90M |
| StockholdersEquity | -28.04M | -39.66M | -12.90M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -4.00K | |
| RetainedEarnings | -584.30M | -534.22M | -472.22M |
| AdditionalPaidInCapital | 556.26M | 494.56M | 459.31M |
| CapitalStock | 4.00K | 0.00 | 3.00K |
| CommonStock | 4.00K | 0.00 | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 62.83M | 73.98M | 73.44M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.68M | 63.85M | 61.75M |
| OtherNonCurrentLiabilities | 4.85M | 4.58M | |
| DerivativeProductLiabilities | 0.00 | 1.09M | 0.00 |
| NonCurrentAccruedExpenses | 0.00 | 4.85M | |
| NonCurrentDeferredLiabilities | 83.00K | 52.00K | 28.00K |
| NonCurrentDeferredRevenue | 83.00K | 52.00K | 28.00K |
| LongTermDebtAndCapitalLeaseObligation | 6.60M | 57.87M | 57.15M |
| LongTermCapitalLeaseObligation | 6.60M | 8.21M | 9.36M |
| LongTermDebt | 49.65M | 47.79M | |
| CurrentLiabilities | 56.15M | 10.13M | 11.69M |
| OtherCurrentLiabilities | 1.79M | 39.00K | |
| CurrentDeferredLiabilities | 224.00K | 172.00K | 518.00K |
| CurrentDeferredRevenue | 224.00K | 172.00K | 518.00K |
| CurrentDebtAndCapitalLeaseObligation | 42.90M | 1.35M | 1.17M |
| CurrentCapitalLeaseObligation | 1.62M | 1.35M | 1.17M |
| CurrentDebt | 41.28M | ||
| OtherCurrentBorrowings | 41.28M | ||
| PayablesAndAccruedExpenses | 11.24M | 8.56M | 10.00M |
| CurrentAccruedExpenses | 9.71M | 7.27M | 7.16M |
| InterestPayable | 839.00K | 1.01M | 974.00K |
| Payables | 1.53M | 1.30M | 2.83M |
| AccountsPayable | 1.53M | 1.30M | 2.83M |
| TotalAssets | 34.80M | 34.33M | 60.54M |
| TotalNonCurrentAssets | 9.61M | 14.97M | 16.14M |
| OtherNonCurrentAssets | 555.00K | 1.69M | 1.70M |
| InvestmentsAndAdvances | 0.00 | ||
| InvestmentinFinancialAssets | 0.00 | ||
| NetPPE | 9.05M | 13.27M | 14.44M |
| AccumulatedDepreciation | -14.85M | -14.26M | -14.98M |
| GrossPPE | 23.90M | 27.53M | 29.42M |
| Leases | 3.61M | 3.78M | 3.77M |
| ConstructionInProgress | 23.00K | 685.00K | 512.00K |
| OtherProperties | 18.59M | 21.32M | 23.41M |
| MachineryFurnitureEquipment | 1.69M | 1.74M | 1.73M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 25.19M | 19.36M | 44.39M |
| OtherCurrentAssets | 3.26M | 2.58M | 3.11M |
| PrepaidAssets | 3.11M | ||
| Inventory | 4.82M | 4.29M | 3.91M |
| FinishedGoods | 1.50M | 1.10M | 1.36M |
| WorkInProcess | 1.44M | 1.18M | 953.00K |
| RawMaterials | 1.88M | 2.00M | 1.59M |
| Receivables | 1.42M | 2.16M | 5.13M |
| AccountsReceivable | 1.42M | 2.16M | 5.13M |
| AllowanceForDoubtfulAccountsReceivable | -100.00K | -100.00K | |
| GrossAccountsReceivable | 1.52M | 2.26M | 5.13M |
| CashCashEquivalentsAndShortTermInvestments | 15.69M | 10.33M | 32.24M |
| OtherShortTermInvestments | 0.00 | 10.00M | |
| CashAndCashEquivalents | 15.69M | 10.33M | 22.25M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -48.33M | -50.97M | -39.33M |
| RepurchaseOfCapitalStock | 0.00 | -330.00K | 0.00 |
| IssuanceOfCapitalStock | 52.73M | 29.46M | 19.97M |
| CapitalExpenditure | -192.00K | -339.00K | -460.00K |
| InterestPaidSupplementalData | 3.86M | 3.92M | 3.81M |
| EndCashPosition | 16.24M | 11.88M | 23.80M |
| BeginningCashPosition | 11.88M | 23.80M | 17.34M |
| ChangesInCash | 4.36M | -11.92M | 6.45M |
| FinancingCashFlow | 52.69M | 29.05M | 20.54M |
| CashFlowFromContinuingFinancingActivities | 52.69M | 29.05M | 20.54M |
| NetOtherFinancingCharges | -62.00K | -243.00K | |
| ProceedsFromStockOptionExercised | 19.00K | 165.00K | 567.00K |
| NetPreferredStockIssuance | 0.00 | -30.00K | 0.00 |
| PreferredStockPayments | 0.00 | -330.00K | 0.00 |
| PreferredStockIssuance | 0.00 | 300.00K | 0.00 |
| NetCommonStockIssuance | 52.73M | 29.16M | 19.97M |
| CommonStockIssuance | 52.73M | 29.16M | 19.97M |
| InvestingCashFlow | -192.00K | 9.66M | 24.79M |
| CashFlowFromContinuingInvestingActivities | -192.00K | 9.66M | 24.79M |
| NetInvestmentPurchaseAndSale | 0.00 | 10.00M | 25.25M |
| SaleOfInvestment | 0.00 | 10.00M | 25.25M |
| PurchaseOfInvestment | 0.00 | ||
| NetPPEPurchaseAndSale | -192.00K | -339.00K | -460.00K |
| SaleOfPPE | 0.00 | ||
| PurchaseOfPPE | -192.00K | -339.00K | -460.00K |
| OperatingCashFlow | -48.14M | -50.63M | -38.87M |
| CashFlowFromContinuingOperatingActivities | -48.14M | -50.63M | -38.87M |
| ChangeInWorkingCapital | -4.04M | -503.00K | -2.17M |
| ChangeInOtherWorkingCapital | 83.00K | -322.00K | -108.00K |
| ChangeInOtherCurrentLiabilities | -1.35M | -1.37M | -1.15M |
| ChangeInPayablesAndAccruedExpense | -2.22M | -1.30M | 1.53M |
| ChangeInAccruedExpense | -2.45M | 261.00K | 769.00K |
| ChangeInPayable | 231.00K | -1.57M | 761.00K |
| ChangeInAccountPayable | 231.00K | -1.57M | 761.00K |
| ChangeInPrepaidAssets | -550.00K | 471.00K | -467.00K |
| ChangeInInventory | -744.00K | -949.00K | -1.94M |
| ChangeInReceivables | 743.00K | 2.97M | -35.00K |
| ChangesInAccountReceivables | 743.00K | 2.97M | -35.00K |
| OtherNonCashItems | 3.68M | 3.36M | 3.93M |
| StockBasedCompensation | 4.35M | 6.49M | 7.09M |
| AssetImpairmentCharge | 2.51M | 151.00K | 0.00 |
| DepreciationAmortizationDepletion | 859.00K | 1.05M | 2.54M |
| DepreciationAndAmortization | 859.00K | 1.05M | 2.54M |
| Depreciation | 2.27M | 2.54M | |
| OperatingGainsLosses | -5.42M | 829.00K | -1.02M |
| GainLossOnInvestmentSecurities | -5.42M | 829.00K | -1.02M |
| GainLossOnSaleOfPPE | 3.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -50.08M | -62.00M | -49.24M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for TTOO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|